US lots added to EpiPen recalls amid fears of defects

3 April 2017
mylan-big

Further lots have been added to the EpiPen (epinephrine) Auto-Injector devices being recalled because it is feared that they might not work.

Last month as many as 81,000 of the allergy injection products, marketed by Netherlands-incorporated drugmaker Mylan (Nasdaq: MYL), had to be recalled after two instances when the devices apparently failed to work in emergencies.

Those devices were distributed in Europe, Japan, Australia and New Zealand, but now Mylan has confirmed a further recall – this time including for products sold in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical